Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment
Authors:
- James Edward TroskoJTJames Edward Trosko
- Chia-Cheng ChangCCChia-Cheng Chang
- 1 March 2010
- journal article
- review article
- Published by Elsevier in Toxicology
- Vol. 270 (1) , 18-34
Abstract
No abstract availableKeywords
This publication has 181 references indexed in Scilit:
- Efficient tumour formation by single human melanoma cellsNature, 2008
- Genomic and Epigenetic Instability in Colorectal Cancer PathogenesisGastroenterology, 2008
- Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factorsCell Research, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Generation of germline-competent induced pluripotent stem cellsNature, 2007
- Stability and flexibility of epigenetic gene regulation in mammalian developmentNature, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessProceedings of the National Academy of Sciences, 2006
- β-Carotene: a cancer chemopreventive agent or a co-carcinogen?Mutation Research - Reviews in Mutation Research, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003